Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy

A 56-year-old man with diabetes, hypertension, and chronic kidney disease presented to the emergency room with a complaint of pain in his right foot. He was found to have tremors. Gabapentin toxicity was suspected and the patient was found to have high gabapentin level (6.3 mcg/ml). Patient was commenced on continuous venovenous hemodiafiltration (CVVHD) and the pharmacokinetics of gabapentin was studied. The patient improved symptomatically and his tremors subsided. In this case report, we describe the successful management of gabapentin toxicity with continuous renal replacement therapy and calculate the clearance of gabapentin which will enable future treatment of gabapentin toxicity by CVVHD.

[1]  C. Chong,et al.  Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia , 2008, Emergency Medicine Journal.

[2]  T. Jensen,et al.  New perspectives on the management of diabetic peripheral neuropathic pain , 2006, Diabetes & vascular disease research.

[3]  A. Doğukan,et al.  Gabapentin‐induced coma in a patient with renal failure , 2006, Hemodialysis international. International Symposium on Home Hemodialysis.

[4]  M. Holtkamp,et al.  Gabapentin–induced severe myoclonus in a patient with impaired renal function , 2006, Journal of Neurology.

[5]  C. O'Donovan,et al.  Gabapentin‐induced Myoclonus in End‐stage Renal Disease , 2005, Epilepsia.

[6]  G. Rosati,et al.  Asterixis and toxic encephalopathy induced by gabapentin , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  S. Migdal,et al.  Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  Miroslav Backonja,et al.  Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. , 2003, Clinical therapeutics.

[9]  J. Asconapé,et al.  Myoclonus Associated with the Use of Gabapentin , 2000, Epilepsia.

[10]  R. W. Schultz,et al.  Pharmacokinetics of gabapentin in subjects with various degrees of renal function , 1994, Clinical pharmacology and therapeutics.